Israel Stocks: Teva, D-Pharm, Can Fite, Partner, Cellcom, Camtek

Israel’s TA-25 index declined for the first time in four days, sliding 0.1 percent to 1,118.62 at 1:40 p.m. in Tel Aviv.

The following stocks rose or fell today. Symbols are in parentheses.

Camtek Ltd. (CAMT) (CAMT IT) tumbled 8.3 percent, the most since Oct. 4, to 8.705 shekels, bringing the company’s two day drop to 11 percent. The maker of optical-inspection systems reported a fourth-quarter loss yesterday.

D-Pharm Ltd. (DPRM) rallied 31 percent, the biggest intraday jump since Bloomberg started tracking the shares in August 2009, to 1.261 shekels. The biopharmaceutical company said it is considering the acquisition of Thrombotech Ltd. which is developing a peptide that improves the efficiency of stroke medication.

Can Fite Biopharma Ltd. (CFBI) advanced 7.4 percent to 0.478 shekel. The biopharmaceutical company said its CF102 drug for the treatment of primary liver cancer received orphan drug status from the U.S. Food and Drug Administration. Ophthalix Inc., a unit, received a patent in China.

Habas H.Z. Investments (1960) Ltd. (HBS) advanced 3.1 percent, the most since Feb. 12, to 5.30 shekels. The investment and holding company said it received early commitments from institutions for about 54.5 million shekels ($15 million) in a tender to extend its series four bonds.

Partner Communications Co. (PTNR) slumped 4.6 percent, the biggest intraday decline since Jan. 29, to 30.05 shekels. Israel’s second-largest mobile-phone company postponed final results until the end of March and forecast a drop in fourth- quarter profit. Cellcom Israel Ltd. (CEL) , the country’s biggest mobile-phone company, fell 3.5 percent to 52.50 shekels, the lowest close on record.

Teva Pharmaceutical Industries Ltd. (TEVA) advanced 1 percent to 167.60 shekels, or the equivalent of $44.71. The U.S.-traded shares of the world’s largest maker of generic drugs jumped 1.3 percent to $45.24 in New York yesterday.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.